+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Case ReportOpen Access

Atypical Presentation of Sarcoidosis with Retroperitoneal Fibrosis, Non-Caseating Granulomatous Perinephric Lesion and Obstructive Uropathy Volume 50- Issue 3

Ramchandani Santosh1*, Syed Ali Aown1, Joseph Guzzo1, Lata Ramchandani, Benjamin Wilcox1 and Glen Markowitz2

  • 1Lehigh Valley Hospital, Allentown, USA
  • 2Columbia University Medical Center, USA

Received: May 04, 2023;   Published: May 15, 2023

*Corresponding author: Ramachandani Santosh, Lehigh Valley Hospital, Allentown, PA, USA

DOI: 10.26717/BJSTR.2023.50.007948

Abstract PDF


A 66 year old female was admitted to the hospital with acute renal failure, hyperkalemia, and anemia. Etiology of her acute renal failure was obscure, and all serologic studies were negative. A kidney biopsy was performed shows interstitial infiltration noncaseating granulomas. CT scan abdomen revealed bilateral kidney enlargement and retroperitoneal fibrosis (RPF). Perinephric tissue also demonstrated dense fibrosis, inflammation and noncaseating granulomas. Treatment was initiated with 80mg of prednisone and bilateral ureteral stents were inserted because of fullness of collecting system seen on CT scan. Over 2 weeks, renal function improved towards normal. Kidney and retroperitoneal findings highly suggested renal sarcoidosis.

Keywords: Sarcoidosis; Acute Kidney Injury; Retroperitoneal Fibrosis and Obstructive Uropathy


Sarcoidosis is a multisystem disease of unknown etiology characterized by noncaseating granulomatous lesions involving primarily lymph nodes, lungs, skin and eyes [1]. Common presentation of sarcoidosis include abnormal calcium metabolism, nephrocalcinosis and lymphadenopathy [2]. We have a very rare case of renal sarcoidosis which presented with acute renal failure, normocalcemia, bradycardia, and retroperitoneal fibrosis causing obstructive uropathy.


A 66-year-old Caucasian smoker female with past medical history significant for hypertension, hyperlipidemia, tobacco use disorder, and COPD was admitted to the hospital with acute renal failure, hyperkalemia and anemia. On further inquiry, the patient reported she had been feeling tired, shortness of breath for 2 weeks and had prescribed Bactrim for bronchitis infection by her PCP. Patient self-discontinued antibiotic due to abdominal pain prior to presentation. On arrival, her blood pressure was 120/79 mmHg, pulse of 52 bpm, respiratory rate 19, temp 97.1, SPO2 94% on 2L oxygen via nasal canula. Physical exam revealed ill-appearing female with 1+ lower extremity pitting edema. Her cardiac rhythm was regular and slow, there was no friction rub or murmur. Her lungs had bilateral wheeze but no rales. Her Initial hemoglobin was 6.7 g/dL, WBC 7.6, serum creatinine 4.37 mg/dl (baseline 0.8–1.1 mg/dl 6 months ago), BUN of 100 mg/dl, potassium of 6.3 meq/l. Urinalysis negative for protein and blood. Microscopy exam showed no RBCs, WBCs or cast. Patient was managed with IV diuretics, glucose and insulin for hyperkalemia. A CT scan of the abdomen (Image 1) demonstrated enlarged kidneys fullness of the collecting system and perinephric retroperitoneal fibrosis. Her urine culture was negative. Kidney biopsy was performed on the 4th hospital day. The perinephric tissue showed dense fibrosis, inflammation, and noncaseating granulomas (Images 2 & 3). The Renal cortex contain 13 glomeruli 5 globally sclerosed and remaining demonstrated ischemic wrinkling.

Image 1.


Image 2.


Image 3.


IF was negative. The interstitium had dense infiltration of lymphocytes, and occasional plasma cells and non-caseating granulomas (Image 4). Acid-fast bacilli and fungal stain were negative. These findings were interpreted as renal sarcoidosis. 125 dihydroxy vitamin D and, angiotensin-converting enzyme were negative. High-resolution CT scan chest and abdomen shows interstitial lung disease and retroperitoneal fibrosis with no evidence of lymphadenopathy. Because of bradycardia cardiac MRI was planned to evaluate of conducting to rule out cardiac sarcoidosis. The patient was treated with prednisone 80 mg daily and bilateral ureteral stents were placed because of possible obstruction due to retroperitoneal fibrosis. After 5 days at the time of discharge the serum creatinine had decreased to 1.1mg/dl. Her wheeze, and bradycardia also resolved on the steroids.

Image 4.



This patient had pulmonary manifested by dyspnea, wheeze, hypoxia and interstitial lung diseases on CT but no perihilar adenopathy. Renal involvement is evident in 11% sarcoid patients [3]. Hypercalcemia and nephrocalcinosis are common manifestations of sarcoidosis which leads to renal insufficiency; however, glomerulopathy, interstitial nephritis, and obstructive uropathy may also occur [3]. Retroperitoneal fibrosis is a late manifestation of sarcoidosis with pulmonary involvement noticed in some studies [4]. There was no evidence of kidney stone, hypercalcemia, proteinuria, hematuria, and nephrocalcinosis in outpatient. At autopsy 40% of patient with sarcoidosis may have renal granuloma [5]. Isolated retroperitoneal fibrosis along with ureteral obstruction is rarely seen in sarcoidosis [4]. There are no clear guidelines on how retroperitoneal fibrosis (RPF) patients should be managed. The main goal is to preserve renal function in RPF. Currently, the suggested treatment is the combination of steroids with ureteral stents in urinary tract obstruction or renal insufficiency [6]. Our patient had a good renal recovery with steroids and ureteral stents. Tamoxifen has been recommended as an alternative to steroids [7,8]. There is limited data on the use of other immunosuppressive drugs, methotrexate [9]. Cyclophosphamide [10]. Azathioprine [11]. and mycophenolate mofetil. Surgical ureterolysis are necessary by laparoscopy in refractory cases [12,13]. Most patients with RPF have a good prognosis but relapses may occur in 15 to 50% of cases [14-17]. and some may progress to ESRD. In RPF, Mortality rate is reported 0-9% [14,15,18-20]. and ESRD of 0-8% [14,16,17]. The risk factors of relapse include a shorter duration treatment with steroids [14]. higher baseline ESR [14]. smoking [16]. and AKI [16]. In this patient the treatment was planning to continue steroid for 6 months to decrease the chance of relapse.


We presented a case of renal sarcoidosis and sarcoid retroperitonea fibrosis leading to renal failure. Our patient fully recovered with steroids and ureteral stents. Larger studies are needed to further explore treatment options and prognosis.


  1. (1999) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160(2): 736-755.
  2. Meyier A, Valeyre D, Bouillon R, Paillard F, Battesti JP, et al. (1985) Resorptive versus absorptive hypercalciuria in sarcoidosis: Correlations with 25-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 and parameters of disease activity. Q J Med 54(215): 269-281.
  3. Godin M, Fillastre J, Ducastelle T, Hemet J, Morere P, et al. (1980) Sarcoidosis. Retroperitoneal fibrosis, renal arterial involvement and unilateral focal glomerulosclerosis. Arch Int Med 140(9): 1240-1242.
  4. Amnon Gil, Yaron Ofer, Mordechai Yigla, Ludmila Goralnik, Shimon Meretyk, et al (2010) Obstructive uropathy caused by retroperitoneal fibrosis presents as a late manifestation of sarcoidosis. Renal Failure 32(9): 1118-1120.
  5. Libacq E, Verhaegen H, Desment V (1970) Renal involvement in sarcoidosis. Postgrad Med J 46: 526–529.
  6. Fry AC, Singh S, Gunda SS, Greg B Boustead, Damian C Hanbury, et al. (2008) Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract 108(3): c213-c220.
  7. Brandt AS, Kamper L, Kukuk S, Haage P, Roth S, et al. (2014) Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int 93(3): 320-325.
  8. Van Bommel EF, Pelkmans LG, van Damme H, Hendriksz TR (2013) Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med 24(5): 444-450.
  9. Alberici F, Palmisano A, Urban ML, Federica Maritati, Elena Oliva, et al. (2013) Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 72(9): 1584-1586.
  10. Binder M, Uhl M, Wiech T, F Kollert, J Thiel, et al. (2012) Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 71(2): 311-312.
  11. Průcha M, Kolombo I, Štádler P (2016) Combination of Steroids and Azathioprine in the Treatment of Ormond's Disease--A Single Centre Retrospective Analysis. Prague Med Rep 117(1): 34-41.
  12. Okumura A, Murakami K, Nozaki T, Fuse H (2005) Laparoscopic ureterolysis for idiopathic retroperitoneal fibrosis. Int J Urol 12(12): 1079-1081.
  13. Stein RJ, Patel NS, Quinn K, Milton Berger, Walter Koff, et al. (2010) Laparoscopic ureterolysis with omental wrap for idiopathic retroperitoneal fibrosis. BJU Int 106(5): 703-707.
  14. Zhao J, Li J, Zhang Z (2019) Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study. Scand J Rheumatol 48(3): 239-245.
  15. Kermani TA, Crowson CS, Achenbach SJ, Luthra HS (2011) Idiopathic retroperitoneal fibrosis: A retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 86(4): 297-303.
  16. Moriconi D, Giannese D, Capecchi R, Riccardo Morganti, Eugenio Orsitto, et al. (2019) Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis. Clin Exp Nephrol 23(9): 1147-1153.
  17. Labidi J, Ariba YB, Chargui S, Bousetta N, Louzir B, et al. (2015) Retroperitoneal fibrosis: A retrospective review of clinical presentation, treatment and outcomes. Saudi J Kidney Dis Transpl 26(4): 816-822.
  18. Moroni G, Gallelli B, Banfi G, Sandri S, Messa P, et al. (2006) Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol Dial Transplant 21(9): 2485-2490.
  19. E Von Bommel, C Siemes, S Van der Veer, S H Han, AWLC Huiskes, et al. (2007) Clinical value of gallium-67 SPECT scintigraphy in the diagnostic and therapeutic evaluation of retroperitoneal fibrosis: A prospective study. J Intern Med 262(2): 224-234.
  20. D Corradi, R Maestri, A Palmisano, S Bosio, P Greco, et al. (2007) Idiopathic retroperitoneal fibrosis: Clinicopathologic features and differential diagnosis. Kidney Int 72(6): 742-753.